<DOC>
	<DOCNO>NCT00026416</DOCNO>
	<brief_summary>RATIONALE : Thalidomide may stop growth cancer stop blood flow tumor . Interferon alfa may interfere growth cancer cell . Combining interferon alfa thalidomide may kill tumor cell . PURPOSE : Phase II trial study effectiveness combine interferon alfa thalidomide treat patient undergone surgery soft tissue sarcoma bone sarcoma .</brief_summary>
	<brief_title>Interferon Alfa Thalidomide Treating Patients With Soft Tissue Sarcoma Bone Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy interferon alfa thalidomide , term time disease progression , patient surgically resect high-risk soft tissue sarcoma bone sarcoma . - Determine incidence metastatic disease overall survival patient treat regimen . - Determine clinical laboratory toxic effect tolerability regimen patient . OUTLINE : Patients receive interferon alfa subcutaneously three time week week 1-60 oral thalidomide daily week 13-60 absence disease progression unacceptable toxicity . Patients follow every 6 week least 2 year . PROJECTED ACCRUAL : A total 20-48 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary metastatic soft tissue sarcoma bone sarcoma high risk recurrence Grade IIIIV tumor great 8 cm Grade IIIIV primary tumor great 5 cm positive surgical margin Grade IIIIV primary tumor great 5 cm distant metastasis resect within 1 year primary surgery No 8 week since prior surgical resection primary metastatic disease Ineligible high priority national institutional study PATIENT CHARACTERISTICS : Age : 18 Performance status : SWOG 02 Life expectancy : More 2 month Hematopoietic : WBC great 3,000/mm^3 Neutrophil count least 1,500/mm^3 Platelet count great 70,000/mm^3 Hemoglobin least 10.0 g/dL Hepatic : Bilirubin le 2.0 mg/dL SGOT SGPT less 3 time upper limit normal ( ULN ) * Alkaline phosphatase less 3 time ULN* No decompensated liver disease No autoimmune hepatitis No coagulation disorder NOTE : * Unless due metastatic disease Renal : Creatinine normal Cardiovascular : No history severely debilitate cardiovascular disease No unstable angina No uncontrolled congestive heart failure No thrombophlebitis Pulmonary : No history severely debilitate pulmonary disease No chronic obstructive pulmonary disease No pulmonary embolism Other : Not pregnant nursing Negative pregnancy test Fertile patient must use 2 form effective contraception 4 week , , 4 week study No acute infection require systemic antibiotic No prior hypersensitivity interferon alfa component injection No diabetes mellitus prone ketoacidosis No severe myelosuppression No history autoimmune disease No preexisting thyroid abnormality thyroid function maintain normal range No clinically significant retinal abnormality No serious medical psychiatric illness would preclude study No prior malignancy except curatively treat carcinoma situ cervix skin cancer PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Prior systemic chemotherapy allow Endocrine therapy : Not specify Radiotherapy : Prior radiotherapy allow Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2003</verification_date>
	<keyword>stage III adult soft tissue sarcoma</keyword>
	<keyword>localize osteosarcoma</keyword>
	<keyword>metastatic osteosarcoma</keyword>
	<keyword>stage II adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
</DOC>